Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental immune drugs, have shown promising early results in patients with advanced non-small cell lung cancer (NSCLC), melanoma, and renal carcinoma. More than 500 patients were treated in the studies of two drugs that target the same immune-suppressive pathway, and according to the investigators there is enough evidence to support wider testing in larger groups of patients. Results of the phase I clinical trials are published online June 2 in The New England Journal of Medicine and presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (1-5 June, Chicago, USA). Read the news release here.
Study mentioned: Topalian SL, et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 Jun 2 [Epub ahead of print] PMID 22658127
No comments:
Post a Comment